This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Cellectis | |
|---|---|
| Name | Cellectis |
| Industry | Biotechnology |
| Founded | 1999 |
| Founders | André Choulika |
| Headquarters | Paris, France |
| Products | Gene-edited cell therapies |
Cellectis
Cellectis is a biotechnology company focused on developing gene-edited cell therapies using engineered nucleases and allogeneic approaches. The company operates within the global biopharmaceutical ecosystem alongside firms such as Novartis, Gilead Sciences, Roche, Pfizer, and AstraZeneca and interacts with research institutions like Institut Pasteur, INSERM, Harvard University, MIT, and Stanford University. Executives and founders include figures active in venture and biotech communities such as André Choulika, who has participated in conferences alongside leaders from Bill & Melinda Gates Foundation, European Investment Bank, and Templeton Foundation.
Founded in 1999 by André Choulika, the company emerged during a period marked by breakthroughs at centers such as Broad Institute, EMBL, Cold Spring Harbor Laboratory, and Salk Institute. Early development involved partnerships with academic groups from Université Paris-Saclay and commercial alliances with biotechnology firms in the San Francisco Bay Area, Boston, and London. The firm pursued capital raises involving investors like Sofinnova Partners, Sequoia Capital, and listings on stock exchanges comparable to Euronext and NASDAQ issuances undertaken by peers such as Moderna and Illumina. Over time, management changes echoed corporate developments seen at Amgen and Biogen, while strategic pivots reflected trends identified by analysts at Goldman Sachs, Morgan Stanley, and JPMorgan Chase & Co..
The company's core platform centers on engineered nucleases, a technology family that includes methods pioneered at University of California, Berkeley, Broad Institute, and EMBL-EBI. Their approach integrates gene-editing tools comparable to innovations from CRISPR Therapeutics, Editas Medicine, and Sangamo Therapeutics and utilizes techniques refined in laboratories such as Geneva University Hospitals and Karolinska Institutet. Manufacturing processes align with standards used by contract development and manufacturing organizations like Catalent, Lonza Group, and WuXi AppTec, and quality frameworks are informed by guidelines from agencies including European Medicines Agency and U.S. Food and Drug Administration. The platform emphasizes allogeneic, off-the-shelf cell products produced under controls similar to those at AstraZeneca plc biologics facilities.
Programs target hematological malignancies and solid tumors with strategies paralleling programs at Novartis for CAR-T, Gilead Sciences for cellular immunotherapies, and investigational pipelines at Bluebird Bio and Kite Pharma. Preclinical and clinical studies have been evaluated in trials overseen by bodies like ClinicalTrials.gov and ethics committees similar to those at Mayo Clinic and Cleveland Clinic. Indications examined range from acute lymphoblastic leukemia treated in protocols influenced by work at St. Jude Children's Research Hospital to solid tumor approaches informed by research at Dana-Farber Cancer Institute and MD Anderson Cancer Center. Clinical collaborators have included principal investigators affiliated with Johns Hopkins University and University College London.
The corporate governance model mirrors structures seen at multinational biopharmaceuticals such as Sanofi, GlaxoSmithKline, and Bristol Myers Squibb. Financial reporting aligns with standards used by firms listed on exchanges similar to Euronext Paris and NASDAQ OMX Group. Operations include research sites comparable to facilities run by Genentech and regional offices in biotech clusters like San Diego, Cambridge, Massachusetts, Shanghai, and Tel Aviv. Board compositions have featured executives and investors with backgrounds from BlackRock, Temasek, and Bertelsmann-affiliated ventures.
Cellectis has engaged in collaborations reminiscent of alliances between Pfizer and BioNTech, or AstraZeneca and Oxford University. Strategic partnerships have involved large pharmaceutical companies, academic centers such as Imperial College London and University of Pennsylvania, and biotech players like Servier and Allogene Therapeutics. Collaborative frameworks follow models used in consortia including Innovative Medicines Initiative and public–private initiatives similar to those backed by the European Commission and National Institutes of Health.
The company’s patent estate relates to engineered nuclease technologies in a landscape contested by entities such as Broad Institute, UC Berkeley, Caribou Biosciences, CRISPR Therapeutics, and Editas Medicine. Patent prosecution and litigation tracks involve legal venues comparable to United States Patent and Trademark Office disputes and proceedings before courts like the United States Court of Appeals for the Federal Circuit and European patent tribunals. Regulatory interactions reflect dossier submissions analogous to those made to the European Medicines Agency and U.S. Food and Drug Administration, with engagement strategies similar to regulatory affairs teams at Johnson & Johnson and Eli Lilly and Company.
Legal and public controversies in the gene-editing sector have involved patent disputes among institutions such as Broad Institute and University of California, policy debates hosted by forums including World Health Organization, and ethical discussions involving panels at UNESCO and academic conferences at Harvard Medical School. Corporate legal matters have sometimes paralleled high-profile cases involving Theranos, Myriad Genetics, and litigations seen in the biotech industry before tribunals such as the High Court of Justice and U.S. District Court for the District of Massachusetts.
Category:Biotechnology companies